Lifevantage Corp (LFVN) stock
LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 16/3023% below fair value
$4.97−0.07 (-1.39%)
Close on Nov 13, 2026Market cap $62.26MP/E 23.7Yield 3.72%
Lifevantage ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lifevantage's ebitda for the twelve months ending Sep 30, 2026 was $6.59M, down 55.7% year over year. For fiscal 2026 it was $8.87M, down 42.2% from the year before. Over ten years it grew -5.3% a year on average. The highest annual figure on record is $21.98M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $8.87M | -42.2% |
| FY2025 | Jun 30, 2025 | $15.36M | +94.0% |
| FY2024 | Jun 30, 2024 | $7.91M | +1.0% |
| FY2023 | Jun 30, 2023 | $7.84M | -27.7% |
| FY2022 | Jun 30, 2022 | $10.84M | -48.6% |
| FY2021 | Jun 30, 2021 | $21.08M | +15.5% |
| FY2020 | Jun 30, 2020 | $18.24M | +55.8% |
| FY2019 | Jun 30, 2019 | $11.71M | +0.5% |
| FY2018 | Jun 30, 2018 | $11.65M | +91.2% |
| FY2017 | Jun 30, 2017 | $6.09M | -60.2% |
| FY2016 | Jun 30, 2016 | $15.31M | -5.4% |
| FY2015 | Jun 30, 2015 | $16.18M | -25.0% |
| FY2014 | Jun 30, 2014 | $21.57M | +57.1% |
| FY2013 | Jun 30, 2013 | $13.73M | -37.5% |
| FY2012 | Jun 30, 2012 | $21.98M | +461.1% |
| FY2011 | Jun 30, 2011 | $3.92M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $594.00K | -79.4% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $2.36M | -18.4% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $2.39M | -50.7% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $1.24M | -70.7% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $2.88M | -14.5% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $2.90M | -22.0% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $4.86M | +71.7% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $4.23M | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $3.37M | +102.0% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $3.72M | +6.1% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $2.83M | +14.6% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$299.00K | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $1.67M | -21.8% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $3.50M | +51.5% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $2.47M | -7.3% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$264.00K | -158.1% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $2.13M | -60.6% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $2.31M | -68.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $2.66M | -9.7% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $454.00K | -92.6% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $5.41M | +16.8% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $7.40M | +5.2% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $2.95M | -21.2% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $6.10M | +40.0% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $4.63M | +48.7% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $7.03M | +13.3% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $3.74M | +37.6% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $4.36M | +327.8% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $3.11M | +76.4% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $6.21M | +32.5% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $2.72M | +5.9% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $1.02M | -61.6% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.77M | +1.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $4.68M | +139.1% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $2.57M | +313.5% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $2.65M | +137.8% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $1.75M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $1.96M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $621.00K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $1.11M | – |
See a number that looks wrong?